Blog Post - AVIM Therapy Patent Portfolio Reaches New Milestone
OBIO | YESTERDAY’S FDA BREAKTHROUGH DEVICE DESIGNATION NEWS
Yesterday, we shared exciting news that Orchestra BioMed has been awarded FDA Breakthrough Device Designation for our novel AVIM therapy. If you missed the announcement, here’s a quick overview of this significant clinical and regulatory milestone:
OBIO | AVIM Therapy Breakthrough Device Designation Shareholder Implications
This week marks a major milestone for Orchestra BioMed that has potentially significant implications for the commercial potential of AVIM therapy that OBIO is pursuing with its strategic partner, Medtronic.
